Cancer-associated fibroblasts: The silent conductors of tumor evolution and therapy refractoriness.

Authors

Fatemeh Kolahchi, Faeze Karimi, Nasim Kheshtchin

Published in

Molecular biology reports. Volume 53. Issue 1. Jul 28, 2026. Epub Jul 28, 2026.

Abstract

Cancer-associated fibroblasts (CAFs) are key elements of the tumor microenvironment and influence cancer growth, progression, metastasis, and treatment resistance. They originate from multiple sources, including resident fibroblasts, stellate cells, epithelial and endothelial cells, and bone marrow-derived precursors, leading to substantial functional and molecular diversity. Most CAF subsets promote tumor development by remodeling the extracellular matrix, releasing growth factors and cytokines, inducing epithelial-mesenchymal transition, and suppressing antitumor immunity. However, some subsets can restrain tumor growth. This heterogeneity makes therapeutic targeting difficult. This review summarizes current knowledge of CAF origins, activation mechanisms, molecular markers, and functional subtypes, emphasizing their contributions to an immunosuppressive tumor microenvironment that limits the effectiveness of immunotherapy. It also discusses emerging therapeutic strategies such as CAF depletion, phenotype reprogramming, and extracellular matrix normalization, along with their potential benefits and challenges.

PMID:
42517964
Bibliographic data and abstract were imported from PubMed on 28 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.